Diagnostic Assessment of Venous Thromboembolism via Novel D-Dimer Assay

Siemens Healthineers has introduced the Innovance D-Dimer 2.0 assay, a CE-marked and FDA 510(k)-cleared in vitro diagnostic test designed to assist clinicians in evaluating patients with suspected venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Venous thromboembolism impacts approximately 10 million individuals globally each year, presenting acute risks when vascular occlusions impede perfusion to critical organs such as the heart, lungs, and brain.

Technical Architecture and Diagnostic Indications
The assay functions by quantifying D-dimer, a degradation product generated via plasmin-mediated proteolysis of cross-linked fibrin. Elevated plasma concentrations serve as an indirect biomarker of active intravascular coagulation and fibrinolysis. The test is indicated for outpatients suspected of deep vein thrombosis or pulmonary embolism when evaluated alongside a validated clinical pretest probability model, such as the Wells score or YEARS algorithm. By achieving high negative predictive value, the assay permits clinicians to safely rule out thrombotic events, thereby preventing unnecessary diagnostic imaging and non-indicated therapeutic interventions.

Beyond venous thromboembolism exclusion, the assay aids in diagnosing and monitoring hypercoagulable states, such as disseminated intravascular coagulation. Disseminated intravascular coagulation is a systemic consumptive coagulopathy driven by severe underlying pathologies, including sepsis, malignancies, and envenomation. Quantitative tracking of fibrin degradation products provides essential parameters for clinical management algorithms in critical care environments.

Workflow Optimization and Operational Efficiency
Modern diagnostic laboratories encounter high test request volumes alongside rigorous turnaround time targets for emergency departments and STAT orders. The assay configuration incorporates ready-to-use liquid reagents and controls that eliminate manual reconstitution steps and minimize pre-analytical handling.

The system operates across a broad network of automated hemostasis analyzers, including the CN-3000 and CN-6000 systems from Siemens Healthineers. Analytical processing times yield results within 11 minutes or less, facilitating rapid emergency department triage. Furthermore, calibration stability parameters extend up to 12 months, reducing instrument calibration frequency and conserving reagent inventory.

Additional Context:
This section details technical specifications and competitive benchmarking not included in the original product announcement

The Innovance D-Dimer 2.0 assay utilizes an immunoturbidimetric technology format standardized in fibrinogen equivalent units. Competitive benchmarking against established quantitative immunoturbidimetric assays such as the Diagnostica Stago STA-Liatest D-Di Plus and the Roche Diagnostics Tina-quant D-Dimer Gen.2 indicates similar analytical sensitivity profiles exceeding 95% and negative predictive values above 99% when paired with clinical pretest probability scoring. Total measuring ranges span from 0.19 mg/L to 35.20 mg/L FEU across compatible analyzer platforms, accommodating both routine exclusion thresholds and high-concentration monitoring required in disseminated intravascular coagulation management.

Edited by Sucithra Mani, Induportals editor – adapted by AI.

www.siemens-healthineers.com